Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
699 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06749730 | Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma | recruiting | Phase 2 | 63 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06405490 | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 24, 2024 |
| NCT05121038 | CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab(CENDIFOX) | active not recruiting | Phase 1 / Phase 2 | 50 | Anup KasiOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06721286 | Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06717464 | Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer | active not recruiting | Phase 2 | 110 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06714604 | Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC(ADVANTAGE) | recruiting | Phase 3 | 432 | Sahlgrenska University HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05321992 | Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand(eCHEC) | recruiting | N/A | 480 | McMaster UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06239532 | HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma | active not recruiting | Phase 2 | 28 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06699459 | Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC(NICRRBTC) | not yet recruiting | Phase 2 | 76 | Sir Run Run Shaw HospitalOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT04423731 | Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) | active not recruiting | — | 251 | Oslo University HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06341764 | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma | recruiting | Phase 2 | 38 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05254171 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer(ASPIRE) | recruiting | Phase 2 / Phase 3 | 600 | Panbela Therapeutics, Inc.INDUSTRY | 10 | Nov 6, 2024 | clinicaltrials |
| NCT06670547 | Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography | not yet recruiting | — | 3,000 | Germans Trias i Pujol HospitalOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT05851534 | Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas(PROMISE-P) | recruiting | N/A | 2,575 | Maastricht University Medical CenterOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06658587 | A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma | not yet recruiting | — | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06656559 | Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Oct 24, 2024 | clinicaltrials |
| NCT05159440 | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 22, 2024 | clinicaltrials |
| NCT05744219 | Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial(IRIS) | recruiting | Phase 3 | 338 | Jon UnossonOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06041009 | Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations | recruiting | — | 2,100 | Qilu Hospital of Shandong UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06648525 | Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | not yet recruiting | Phase 2 | 68 | Harbin Medical UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06649474 | Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1(HEPATOXALI) | recruiting | N/A | 100 | University Hospital, Clermont-FerrandOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04183712 | Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA | recruiting | Phase 2 | 102 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06645067 | Assessment and Modulation of Energy Balance in Cachectic Patients Using Adapted Physical Activity(EMC2APA) | not yet recruiting | — | 10 | University of Rennes 2OTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT04195503 | Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma | enrolling by invitation | N/A | 10 | University Health Network, TorontoOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04571294 | Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy(PALN) | recruiting | N/A | 180 | Humanitas Hospital, ItalyOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05638698 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA) | active not recruiting | Phase 2 | 24 | University of Kansas Medical CenterOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06567600 | Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 43 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06434493 | Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma(EMPHATIC) | not yet recruiting | N/A | 30 | The Christie NHS Foundation TrustOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06079346 | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer(STOP-PC) | recruiting | Phase 2 / Phase 3 | 455 | Oncotelic Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06276803 | The LINFU® U.S. Registry for the in the General Population Without Risk Factors | not yet recruiting | — | 500 | Adenocyte, LLCINDUSTRY | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06530823 | Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 38 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06531291 | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 80 | RenJi HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06490198 | Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin | not yet recruiting | Phase 1 | 30 | Chang Gung Memorial HospitalOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06298968 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05779917 | Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04340986 | Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma(CHC/CC) | recruiting | — | 1,250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06463548 | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma | not yet recruiting | N/A | 30 | Yunpeng LiuOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06399172 | OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy(OSPRItaly) | not yet recruiting | — | 50 | OncoSil Medical LimitedINDUSTRY | 0 | May 3, 2024 | clinicaltrials |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | recruiting | Phase 2 | 20 | Lei ZHAOOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06369896 | Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures(Spy+IDUS) | not yet recruiting | — | 36 | Soonchunhyang University HospitalOTHER | 0 | Apr 17, 2024 | clinicaltrials |
| NCT06349278 | Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX(PDAC-LIV) | recruiting | N/A | 15 | Laval UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05187312 | Registry for Advanced Endoscopy(ERDB) | recruiting | — | 1,000 | Region StockholmOTHER_GOV | 1 | Apr 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 27, 2024source: clinicaltrials